Archive: 03/01/2012

Pirfenidone: Extent of added benefit assessed

Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since the beginning of 2011. ...

Alzheimer's damage occurs early

The first changes in the brain of a person with Alzheimer's disease can be observed as much as ten years in advance - ten years before the person in question has become so ill that he or she can be diagnosed with the disease. ...

Researchers make less carcinogenic cigarette

(Medical Xpress) -- Though emphasizing that quitting is the best remedy to combat health problems for smokers, Cornell researchers have found a way to make cigarettes less toxic.

Not equal: Quality of care, cost for PAD sufferers

Although minimally invasive (endovascular) treatments for patients with peripheral arterial disease (PAD) result in shorter hospital stays and the potential to save Medicare millions of dollars each year, a new study reveals ...

page 4 from 5